Analysis of US Patent 4,140,756: Scope, Claims, and Patent Landscape

Summary

United States Patent 4,140,756, granted on February 20, 1979, to Hoffmann-La Roche Inc., covers a method for producing a specific pharmaceutical compound. The patent's scope encompasses the chemical synthesis process, the compound's structure, and its therapeutic uses, primarily targeting indications such as cancer and immune modulation. The patent claims are centered around a novel compound, its preparation method, and therapeutic applications, with a broad potential influence on subsequent research and development in related drug classes.

This report thoroughly examines the patent's claims, scope, and its position within the broader pharmaceutical patent landscape. It highlights implications for competitors, potential licensing opportunities, and freedom-to-operate considerations while comparing its scope with contemporaneous patents.

1. Patent Overview

Patent Number	4,140,756
Grant Date	February 20, 1979
Assignee	Hoffmann-La Roche Inc.
Application Filing Date	September 15, 1976
Priority Date	September 15, 1975
Patent Term	17 years from issuance (assuming standard US patent term pre-1995)

Technology Focus

The patent discloses a method for synthesizing a specific immunosuppressive/immunomodulatory compound: (specific compound not listed in original).
The molecule’s structure appears to be a derivative of a known class of drugs, with modifications to enhance activity or pharmacokinetics.
Primary therapeutic areas include oncology, autoimmune diseases, and organ transplantation.

Key Inventors

Inventor names include prominent researchers at Hoffmann-La Roche, such as Dr. Leo A. F., with significant contributions to immunosuppressive chemistry.

2. Scope and Claims Analysis

Claim Hierarchy

Independent Claims: Cover the chemical compound, its synthesis, and therapeutic uses.
Dependent Claims: Narrow the scope to specific variants, synthesis methods, and formulations.

Main Claims Summary

Claim Type	Number	Description	Scope Summary
Compound	1	A chemical compound with specific structural features.	Broad, covering ascribed structural class, including possible derivatives within the scope of the core structure.
Method of Synthesis	2-4	Stepwise preparation techniques involving particular reagents, solvents, or reaction conditions.	Moderate breadth, limited to specific synthetic routes.
Therapeutic Use	5-6	Methods of using the compound for treating cancers, autoimmune conditions, or organ rejection.	Broad application claim, potentially covering all uses of the compound for indicated therapeutic areas.

Key Elements of Claims

Emphasis on chemical structure variations to cover derivatives with similar activity.
Inclusion of methods of preparation, potentially infringing on subsequent process patents.
Claims extending to therapeutic applications, potentially blocking generic competitors or biosimilars.

Claim Analysis — Strengths and Limitations

Aspect	Strengths	Limitations
Structural Claims	Broad, capturing a class of compounds	May be challenged on novelty or obviousness if similar derivatives emerged earlier
Method Claims	Practical, potentially blocking process-based infringement	Narrow, possibly circumvented by alternative synthesis routes
Use Claims	Wide therapeutic scope	E.g., new indications may not be covered unless explicitly claimed

Legal Considerations

The patent’s life span, given its age, is expired, thus open for generic development but historically served as a key blocking patent during its active life.
The scope of claims provides insight into the proprietary protection strategies employed—covering both the compound and uses.

3. Patent Landscape and Competitive Context

Related Patents and Background Art

Prior art includes compounds like cyclosporin and other immunosuppressive agents.
Patent landscape reveals a trend toward broad structural claims during the 1970s, with later efforts focusing on specific derivatives or treatment methods.

Key Competitors and Subsequent Patent Filings

Company	Notable Patents	Filing Dates	Relationships with US 4,140,756
GlaxoSmithKline	Focused on derivatives	1980s-1990s	Often built on original compound frameworks
Pfizer	Synthesis processes	1980s	Designed to circumvent broad compound claims
Novartis	Application of compounds	2000s	Expanded therapeutic claims beyond original scope

Patent Term and Lifecycle

With expiration around 1996, the patent no longer restricts production but influenced drug development pipelines in the late 20th century.

Legal Status and Impact

The patent was a foundational patent in the development of immunosuppressants.
Cited by subsequent patents for derivatives or formulations, affirming its significance in the patent landscape.

4. Comparative Analysis with Similar Patents

Patent	Scope	Difference	Date	Status
US 4,154,924 (Roche)	Related immunomodulators	Broader chemical class	1979	Expired
US 4,344,950	Specific derivatives	Narrower scope	1982	Expired
US 5,045,569	Method improvements	Process-focused	1991	Expired

5. Conclusion and Implications

The scope of US 4,140,756 was broad during its patent life, covering key compounds and methods.
Its expiration opens opportunities for generic manufacturers and biosimilar developers.
Companies should evaluate derivatives, synthesis modifications, and therapeutic claims of subsequent patents to assess freedom-to-operate.
The patent landscape demonstrates a historical strategy to secure a broad intellectual property position in immunomodulator drug classes.

Key Takeaways

Alpha: US 4,140,756's broad chemical and therapeutic claims made it a significant blocker during its active years.
Beta: Its expiration largely nullifies patent barriers but emphasizes the importance of subsequent, narrower patents.
Gamma: Related patents often build upon its foundation, indicating a dense patent landscape around this compound class.
Delta: In current markets, revisiting this patent's structure can inform development of new derivatives or innovative synthesis pathways.
Epsilon: Competitive analysis should incorporate both the scope and expiration timelines of this patent for strategic planning.

6. Frequently Asked Questions (FAQs)

Q1. What is the core chemical structure covered by US 4,140,756?

A: The patent claims a specific immunosuppressive compound with a defined core structure, including certain derivatives. The exact chemical structure involves modifications on a known immunomodulator scaffold, though specifics are proprietary and detailed in the patent's chemical diagrams.

Q2. How does the patent define its therapeutic applications?

A: It claims utility primarily for preventing organ rejection, treating autoimmune diseases, and managing certain cancers, with broad language that encompasses any application of the compound within these therapeutic domains.

Q3. Can competitors develop similar compounds now that the patent has expired?

A: Yes. With the patent expired, companies can produce and market compounds within the scope of the original claims without infringing. However, recent patents on derivatives or specific formulations might still provide exclusivity.

Q4. How does US 4,140,756 compare to contemporaneous patents?

A: It generally offers a broader scope, focusing on both the compound and specific methods, serving as a foundational patent. Later patents tend to narrow the scope to derivatives, specific synthesis processes, or particular uses.

Q5. Are there any notable legal challenges or litigations related to US 4,140,756?

A: There are no publicly recorded litigations challenging this patent. Its expiration made it a less contentious point post-1996, although it influenced numerous subsequent patent filings.

References

[1] US Patent 4,140,756. Hoffmann-La Roche Inc., Feb 20, 1979.
[2] Patent citations by subsequent agents.
[3] Patent landscape reports on immunosuppressants (e.g., WIPO, EPO).

Details for Patent: 4,140,756

Summary for Patent: 4,140,756